Hiroaki Takaya

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

Kosuke Kaji, Hiroaki Takaya, Soichiro Saikawa et al. · World Journal of Gastroenterology · 2017 · 102 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway

Koji Ishida, Kosuke Kaji, Shinya Sato et al. · The Journal of Nutritional Biochemistry · 2020 · 87 citations · Full text

Life Sciences, Pharmacology, Toxicology +16

Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis

Masanori Furukawa, Kei Moriya, Jiro Nakayama et al. · Hepatology Research · 2020 · 86 citations · Full text

Life Sciences, Microbiology, Pathology +17

ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child‐Turcotte‐Pugh score and the Model for End‐Stage Liver Disease score

Hiroaki Takaya, Masahito Uemura, Yoshihiro Fujimura et al. · Hepatology Research · 2012 · 49 citations · Full text

Medicine, Internal Medicine, Pathology +17

von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C

Hiroaki Takaya, Hideto Kawaratani, Yuki Tsuji et al. · United European Gastroenterology Journal · 2018 · 48 citations · Full text

Medicine, Pathology, Carcinogenesis +16